-

06:58:01 AM

ABEO Stock News

ABEO - Abeona Therapeutics Inc

03/29/23 7:30 AM

Nasdaq : ABEO

earnings

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atrophy Strengthened senior

RHEA-AI

neutral

03/24/23 7:30 AM

Nasdaq : ABEO

management

Abeona Therapeutics Announces New Employee Inducement Grants

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, Abeona granted restricted stock equity awards to six employees as an inducement for them to accept

RHEA-AI

very positive

03/16/23 7:30 AM

Nasdaq : ABEO

clinical trial

Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the

RHEA-AI

neutral

03/14/23 7:30 AM

Nasdaq : ABEO

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

Advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt Disease, X-linked Retinoschisis (XLRS), and Autosomal Dominant Optic Atrophy (ADOA) To submit first pre-Investigational New Drug (IND) application meeting request this month NEW

RHEA-AI

positive

11/14/22 7:30 AM

Nasdaq : ABEO

earnings

Abeona Therapeutics Reports Third Quarter 2022 Financial Results

Abeona Therapeutics Inc.

RHEA-AI

neutral

11/03/22 7:31 AM

Nasdaq : ABEO

Abeona Therapeutics Announces $35 Million Private Placement Financing

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of its common stock, and, in lieu of shares of common stock, pre-funded warrants exercisable for

RHEA-AI

neutral

11/03/22 7:30 AM

Nasdaq : ABEO

clinical trial

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

Co-primary endpoint measuring 50% wound healing, other endpoints measuring 75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greater magnitude of pain reduction benefit was observed in post-hoc analysis of EB-101 treated wounds with

RHEA-AI

positive

10/19/22 7:30 AM

Nasdaq : ABEO

clinical trial

Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophic

RHEA-AI

neutral

10/04/22 7:30 AM

Nasdaq : ABEO

clinical trial

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s pivotal Phase 3 VIITAL™ study of its

RHEA-AI

neutral

09/22/22 7:30 AM

Nasdaq : ABEO

conferences

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

ABEO Data

IndustryPharmaceutical Preparation Manufacturing
Websiteabeonatherapeutics.com
CeoJoao Siffert
Security nameAbeona Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees76
Tags
- Health Technology
- Pharmaceuticals: Generic
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1330 Avenue of the Americas Fl 33
StateNew York
CityNew York
Zip10019-5442
CountryUS
Phone16468134701

About Abeona Therapeutics Inc

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.